Abstract: Techniques for adjusting the strengths of signals received from a transmitter based on the transmitter's likely location are disclosed herein. An example method includes receiving, by one or more processors, location information corresponding to one or more respective areas expected to be visited by an individual; receiving, by the one or more processors, measurements indicative of signal strengths of one or more signals transmitted by a transmitter associated with the individual and received by one or more receivers configured to receive one or more signals transmitted by the transmitter, the one or more receivers being positioned at respective receiver locations corresponding to one or more respective areas; and adjusting, by the one or more processors, the received measurements indicative of the signal strengths of the one or more signals transmitted by the transmitter based on the one or more respective areas expected to be visited by the individual.

Abstract: A label modification unit may receive a label modification input that indicates a label modification associated with content being written to a label or erased from the label. The label modification unit may identify an area of the label that is associated with the label modification according to the label modification input. The label modification unit may determine, based on a size of the area, a spot size of a light beam that is configured to be emitted by a laser printhead to modify the content within the area. The label modification unit may determine, based on the spot size and the content, an optical path configuration for the laser printhead. The label modification unit may operate the laser printhead according to the optical path configuration to write the content to the area or erase the content from the area.

Abstract: Methods of treatment and pharmaceutical formulation configured to improve the cure rate of patients with solid tumors when treated with radiotherapy are provided. The methods and treatments use an inhibitor of the CXCL12/CXCR4 pathway. The inhibitors prevent the formation of new blood vessels into a tumor that is being treated with radiotherapy. The inhibitor may be continuously infused intravenously towards the end of radiotherapy and continuing thereafter.

Abstract: Compositions and methods for inhibiting the growth of solid tumors following radiation treatment are described. The compositions and methods target matrix metalloproteinases and bone marrow-derived cells expressing matrix metalloproteinases.

Abstract: Compositions and methods for inhibiting the growth of solid tumors following radiation treatment are described. The compositions and methods target matrix metalloproteinases and bone marrow-derived cells expressing matrix metalloproteinases.

Abstract: A genetically-engineered anaerobic organism is provided which, under anaerobic conditions present in a solid tumor, produces an enzyme capable of catalyzing the conversion of a prodrug to its highly cytotoxic product in situ and methods of treating tumors using same.

Abstract: A genetically-engineered anaerobic organism is provided which, under anaerobic conditions present in a solid tumor, produces an enzyme capable of catalyzing the conversion of a prodrug to its highly cytotoxic product in situ and methods of treating tumors using same.

Abstract: A genetically-engineered anaerobic organism is provided which, under anaerobic conditions present in a solid tumor, produces an enzyme capable of catalyzing the conversion of a prodrug to its highly cytotoxic product in situ and methods of treating tumors using same.